![The F-35’s future: The power and cooling competition that could change everything [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/09/240924_F35_moon_USAF-scaled-e1727200160419.jpg?#)
ASCO: Roche details Itovebi's survival benefit in certain breast cancers, further backing blockbuster plan
Itovebi, when added to Pfizer’s Ibrance and AstraZeneca’s Faslodex, cut the risk of death by 33% in a phase 3 trial of certain breast cancer patients.
Itovebi, when added to Pfizer’s Ibrance and AstraZeneca’s Faslodex, cut the risk of death by 33% in a phase 3 trial of certain breast cancer patients.
